Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma (NHL), accounting for about 1 out of every 3 lymphomas in the United States.

DLBCL occurs in both men and women, although it is slightly more common in men. DLBCL can occur in childhood, however its incidence generally increases with age, and roughly half of patients are over the age of 60 years.

DLBCL is an aggressive (fast-growing) lymphoma that can arise in lymph nodes and often the spleen, liver, bone marrow, or other organs are also affected. Often, the first sign of DLBCL is a painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain.

**SUBTYPES OF DLBCL**

There are several subtypes of DLBCL that may affect a patient’s prognosis (how well a patient will do with standard treatment) and treatment options. Doctors determine the subtype based on testing of the tumor tissue as well as the clinical presentation (e.g., location). Each DLBCL subtype has a different prognosis and may be treated differently. The most common subtype of DLBCL is called diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), and it can further be subdivided into germinal center B-cell-like (GCB) and activated B-cell-like (ABC) subtypes, which refers to the cell of origin (i.e., the origin of the cell that turned into a lymphoma). Increasingly, doctors are recognizing the biological complexity of DLBCL, and new subtypes may emerge in the near future. In some cases, lymphomas that were previously considered to be a subtype of DLBCL are now considered separately from DLBCL; e.g., high-grade B-cell lymphoma (HGBL) demonstrates specific genetic abnormalities that may affect outcomes. For more information, patients should view the High-Grade B-Cell Lymphoma fact sheet on the Lymphoma Research Foundation’s (LRF’s) website (lymphoma.org/publications).

**RELAPSED OR REFRACTORY DISEASE**

Although DLBCL is often cured, up to 40% of patients can relapse (disease returns after treatment) or become refractory (disease does not respond to treatment). These patients are eligible for second-line treatment, which can reduce symptoms, control cancer growth, provide a second chance at cure, and extend life.

**TREATMENT OPTIONS**

Early evaluation at a specialized lymphoma management center is recommended for patients with relapsed/refractory DLBCL. Treatment options will depend on whether or not you are eligible for a stem cell transplant [see Table 1].
### Patients Who Are Refractory to First-Line Chemoimmunotherapy or Relapsed within 1 Year of First-Line Chemoimmunotherapy

<table>
<thead>
<tr>
<th>Preferred second-line treatment is CAR T cell therapy</th>
<th>Axicabtagene ciloleucel (Yescarta)</th>
<th>Lisocabtagene maraleucel (Breyanzi)</th>
</tr>
</thead>
</table>

### Patients Who Are Candidates for a Stem Cell Transplant

<table>
<thead>
<tr>
<th>Preferred second-line treatment is chemotherapy</th>
<th>DHAP +/- rituximab (Rituxan)</th>
<th>DHAX +/- rituximab (Rituxan)</th>
<th>GDP +/- rituximab (Rituxan)</th>
<th>ICE +/- rituximab (Rituxan)</th>
<th>ESHAP +/- rituximab (Rituxan)</th>
<th>GemOx +/- rituximab (Rituxan)</th>
<th>MNE +/- rituximab (Rituxan)</th>
</tr>
</thead>
</table>

### Patients Who Are Not Candidates for a Stem Cell Transplant

| Preferred second-line treatment is chemotherapy | GemOx +/- rituximab (Rituxan) | CEPP +/- rituximab (Rituxan) | CEOP +/- rituximab (Rituxan) | Dose-adjusted EPOCH +/- rituximab (Rituxan) | GDP +/- rituximab (Rituxan) | Germinite and vinorelbine +/- rituximab (Rituxan) | Tafasitamab-cxix (Monjuvi) and lenalidomide (Remvilid) | Lisocabtagene maraleucel (Breyanzi) |
|---|---|---|---|---|---|---|---|

<table>
<thead>
<tr>
<th>Other second-line regimens</th>
<th>Polatuzumab vedotin (Polivy) +/- bendamustine (Treanda)</th>
<th>Loncastuximab tesirine (Zynlonta)</th>
<th>Tisagenlecleucel (Kymriah)</th>
<th>Lisocabtagene maraleucel (Breyanzi)</th>
<th>Selinexor (Xpovio)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Additional lines of therapy</th>
<th>Axicabtagene ciloleucel (Yescarta)</th>
<th>Lisocabtagene maraleucel (Breyanzi)</th>
<th>Polatuzumab vedotin (Polivy) +/- rituximab (Rituxan) and +/- bendamustine (Treanda)</th>
<th>Loncastuximab tesirine (Zynlonta)</th>
<th>Tisagenlecleucel (Kymriah)</th>
<th>Lisocabtagene maraleucel (Breyanzi)</th>
<th>Selinexor (Xpovio)</th>
</tr>
</thead>
</table>

CAR T cell: chimeric antigen receptor T cell; CEPP: cyclophosphamide, etoposide, prednisone and procarbazine; CEOP: cyclophosphamide, etoposide, vincristine and prednisone; DHAP: dexamethasone, cisplatin and cytarabine; DHAX: dexamethasone, cytarabine and oxaliplatin; DLBCL: diffuse large B-cell lymphoma; GDP: gemcitabine, dexamethasone and cisplatin or carboplatin; ICE: ifosfamide, carboplatin and etoposide; EPOCH: etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin; ESHAP: etoposide, methylprednisolone, cytarabine and cisplatin; GemOx: gemcitabine and oxaliplatin.

For patients who do not respond to first-line chemoimmunotherapy (e.g., R-CHOP) or who progress within 12 months of first-line chemoimmunotherapy, chimeric antigen receptor T cells (CAR T cells) may be an option. For patients who experience a recurrence of lymphoma beyond 12 months, second-line chemoimmunotherapy is typically used. In patients who are able to achieve a good response to chemoimmunotherapy, high-dose chemotherapy with autologous stem cell transplantation may be recommended to consolidate their successful second-line treatment.

Patients in complete remission undergoing a stem cell transplant commonly receive their own stem cells (autologous stem cell transplant). Occasionally, a patient will receive stem cells from a donor (allogeneic stem cell transplant). After a stem cell transplant, patients may also receive involved-site radiation therapy (ISRT) to treat a specific area.

Relapsed/refractory patients who are not candidates for or who choose not to have a stem cell transplant have other treatment alternatives. Chemotherapies such as bendamustine (Treanda) or gemcitabine (Gemzar), or targeted drugs like lenalidomide (Revlimid) may be used in these patients in combination with rituximab (Rituxan) or other monoclonal antibodies. Patients with relapsed or refractory DLBCL after two prior therapies may also be eligible for treatment with polatuzumab vedotin-piiq (Polivy) or selinexor (Xpovio). Relapsed/refractory disease in adult patients can also be treated with tafasitamab-cxix.
TREATMENTS UNDER INVESTIGATION

Many novel individual and combination therapies are currently being studied in clinical trials for the treatment of patients with relapsed/refractory DLBCL. Some of the investigational drugs under development are listed below (Table 2).

Table 2. Selected Agents Under Investigation for DLBCL in Phase 2-3 Clinical Trials

<table>
<thead>
<tr>
<th>Agent</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Copanlisib (Aliqopa)</td>
<td>Targeted therapy; PI3K inhibitor</td>
</tr>
<tr>
<td>DTRM-555</td>
<td>Targeted therapy; BTK inhibitor</td>
</tr>
<tr>
<td>PBCAR0191</td>
<td>CAR T cell; anti-CD19</td>
</tr>
<tr>
<td>PBCAR20A</td>
<td>CAR T cell; anti-CD20</td>
</tr>
<tr>
<td>Odronextamab</td>
<td>Immunotherapy; bispecific antibody</td>
</tr>
<tr>
<td>Glofitamab</td>
<td>Immunotherapy; bispecific antibody</td>
</tr>
<tr>
<td>Epcoritamab (GEN3013)</td>
<td>Immunotherapy: bispecific antibody</td>
</tr>
<tr>
<td>Relmacabtagene autoleucel (Relma-cell, JWCAR029)</td>
<td>Autologous CAR T cell; anti-CD19</td>
</tr>
<tr>
<td>Venetoclax (Venclexta)</td>
<td>Targeted therapy; BCL-2 inhibitor</td>
</tr>
<tr>
<td>Zilovertam vedotin (MK-2140)</td>
<td>Immunotherapy; antibody-drug conjugate</td>
</tr>
</tbody>
</table>

Abbreviations: BCL-2, B-cell lymphoma 2; BTK, Bruton tyrosine kinase; CAR, chimeric antigen receptor; HDAC, histone deacetylase; PD-1, programmed cell death protein 1; PI3K, phosphoinositide 3-kinase.

Clinical trials are investigating the use of these agents at various treatment stages and for specific patient populations, including patients with relapsed/refractory disease. For example, because patients with the GCB subtype may have a better response to standard R-CHOP chemotherapy treatment than those with the ABC subtype, researchers are exploring new treatments that specifically improve outcomes for patients with ABC DLBCL. Optimal treatment strategies for HGBL are also being actively investigated; view the High-Grade B-Cell Lymphoma fact sheet on LRF’s website for more information (lymphoma.org/publications). Clinical trials investigating these drugs are in various phases of development. It is critical to remember that today’s scientific research is continuously evolving. Treatment options may change as new treatments are discovered and current treatments are improved, so it is important that patients check with their physician or with LRF for any treatment updates that may have recently emerged.

CLINICAL TRIALS

Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients with lymphoma. Patients interested in participating in a clinical trial should view the Understanding Clinical Trials fact sheet on LRF’s website (lymphoma.org/publications), talk to their physician, or contact the LRF Helpline for an individualized clinical trial search by calling (800) 500-9976 or emailing helpline@lymphoma.org.

FOLLOW-UP

Patients with lymphoma should have regular visits with a physician who is familiar with their medical history and the treatments they have received. Medical tests (CT scans and PET scans) may be required at various times during remission to evaluate the need for additional treatment. Some treatments can cause long-term side effects or late side effects, which can vary based on duration and frequency of treatments, age, gender, and the overall health of each patient at the time of treatment. A physician will check for these effects during follow-up care. Visits may become less frequent the longer the disease remains in remission.

Patients and their caregivers are encouraged to keep copies of all medical records and test results as well as information on the types, amounts, and duration of all treatments received. This documentation will be important for keeping track of any side effects resulting from treatment or potential disease recurrences. LRF’s award-winning Focus On Lymphoma mobile app and Lymphoma Care Plan (lymphoma.org/publications) can help patients manage this documentation.
LRF’S HELPLINE AND LYMPHOMA SUPPORT NETWORK

A lymphoma diagnosis often triggers a range of feelings and concerns. In addition, cancer treatment can cause physical discomfort. The LRF Helpline staff members are available to answer your general questions about a lymphoma diagnosis and treatment information, as well as provide individual support and referrals to you and your loved ones. Callers may request the services of a language interpreter. A part of the Helpline is LRF’s one-to-one peer support programs, Lymphoma Support Network. This program connects patients and caregivers with volunteers who have experience with relapsed/refractory DLBCL, similar treatments, or challenges, for mutual emotional support and encouragement. Patients and loved ones may find this useful whether the patient is newly diagnosed, in treatment, or in remission.

MOBILE APP

Focus On Lymphoma is the first mobile application [app] that provides patients and caregivers comprehensive content based on their lymphoma subtype, including relapsed/refractory DLBCL, and tools to help manage their lymphoma such as, keep track of medications and blood work, track symptoms, and document treatment side effects. The Focus On Lymphoma mobile app is available for download for iOS and Android devices in the Apple App Store and Google Play. To learn more about any of these resources, visit our website at lymphoma.org, or contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org.

LRF appreciates the expertise and review of our Editorial Committee:

Leo I. Gordon, MD, FACP
Co-Chair
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Kristie A. Blum, MD
Co-Chair
Emory University School of Medicine

John Allan
Weill Cornell Medicine

Jennifer E. Amengual, MD
Columbia University

Jonathon Cohen
Emory University School of Medicine

Alex Herrera, MD
City of Hope

Shana Jacobs, MD
Children’s National Hospital

Manali Kamdar, MD
University of Colorado

Peter Martin, MD,
Weill Cornell Medicine

Anthony Mato, MD
Memorial Sloan Kettering Cancer Center

Neha Mehta-Shah, MD, MSCI
Washington University School of Medicine in St. Louis

Pierluigi Porcu, MD
Thomas Jefferson University

Contact LRF:
Helpline: [800] 500-9976
Email: helpline@lymphoma.org
www.lymphoma.org

Supported through grants from:

Understanding Lymphoma fact sheet series is published by the Lymphoma Research Foundation (LRF) for the purpose of informing and educating readers. Facts and statistics were obtained using published information, including data from the Surveillance, Epidemiology, and End Results (SEER) Program. Because each person’s body and response to treatment is different, no individual should self-diagnose or embark upon any course of medical treatment without first consulting with his or her physician. The medical reviewer, the medical reviewer’s institution, and LRF are not responsible for the medical care or treatment of any individual.

© 2022 Lymphoma Research Foundation

Last updated 2022